Piramal Pharma Limited (PPLPHARMA) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.048x

Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) has a cash flow conversion efficiency ratio of 0.048x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs3.69 Billion ≈ $39.91 Million USD) by net assets (Rs77.58 Billion ≈ $838.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Piramal Pharma Limited - Cash Flow Conversion Efficiency Trend (2021–2025)

This chart illustrates how Piramal Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PPLPHARMA current and long-term liabilities for a breakdown of total debt and financial obligations.

Piramal Pharma Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Piramal Pharma Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Foot Locker Inc
NYSE:FL
0.002x
ARIS MNG.CORP.
F:ZP1
N/A
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
0.095x
Krungthai Card Public Company Limited
BK:KTC-R
-0.012x
Epoxy Base Electronic Material Corp Ltd
SHG:603002
0.002x
Suzhou Gold Mantis Construction Decoration Co Ltd
SHE:002081
0.030x
Inv La Constru
SN:ILC
0.106x
Braze Inc
NASDAQ:BRZE
0.035x

Annual Cash Flow Conversion Efficiency for Piramal Pharma Limited (2021–2025)

The table below shows the annual cash flow conversion efficiency of Piramal Pharma Limited from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see PPLPHARMA stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs81.25 Billion
≈ $878.74 Million
Rs8.92 Billion
≈ $96.50 Million
0.110x -13.51%
2024-03-31 Rs79.11 Billion
≈ $855.58 Million
Rs10.05 Billion
≈ $108.64 Million
0.127x +77.74%
2023-03-31 Rs67.73 Billion
≈ $732.53 Million
Rs4.84 Billion
≈ $52.33 Million
0.071x +87.46%
2022-03-31 Rs66.97 Billion
≈ $724.21 Million
Rs2.55 Billion
≈ $27.60 Million
0.038x +350.09%
2021-03-31 Rs41.01 Billion
≈ $443.47 Million
Rs347.20 Million
≈ $3.75 Million
0.008x --

About Piramal Pharma Limited

NSE:PPLPHARMA India Drug Manufacturers - Specialty & Generic
Market Cap
$2.29 Billion
Rs212.14 Billion INR
Market Cap Rank
#5775 Global
#251 in India
Share Price
Rs160.30
Change (1 day)
-0.97%
52-Week Range
Rs133.27 - Rs219.04
All Time High
Rs293.55
About

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more